Literature DB >> 26617318

Characterization and comparison of two novel nanosystems associated with siRNA for cellular therapy.

E M André1, A Pensado2, P Resnier1, L Braz3, A M Rosa da Costa4, C Passirani1, A Sanchez5, C N Montero-Menei6.   

Abstract

To direct stem cell fate, a delicate control of gene expression through small interference RNA (siRNA) is emerging as a new and safe promising strategy. In this way, the expression of proteins hindering neuronal commitment may be transiently inhibited thus driving differentiation. Mesenchymal stem cells (MSC), which secrete tissue repair factors, possess immunomodulatory properties and may differentiate towards the neuronal lineage, are a promising cell source for cell therapy studies in the central nervous system. To better drive their neuronal commitment the repressor Element-1 silencing transcription (REST) factor, may be inhibited by siRNA technology. The design of novel nanoparticles (NP) capable of safely delivering nucleic acids is crucial in order to successfully develop this strategy. In this study we developed and characterized two different siRNA NP. On one hand, sorbitan monooleate (Span(®)80) based NP incorporating the cationic components poly-l-arginine or cationized pullulan, thus allowing the association of siRNA were designed. These NP presented a small size (205 nm) and a negative surface charge (-38 mV). On the other hand, lipid nanocapsules (LNC) associating polymers with lipids and allowing encapsulation of siRNA complexed with lipoplexes were also developed. Their size was of 82 nm with a positive surface charge of +7 mV. Both NP could be frozen with appropriate cryoprotectors. Cytotoxicity and transfection efficiency at different siRNA doses were monitored by evaluating REST expression. An inhibition of around 60% of REST expression was observed with both NP when associating 250 ng/mL of siRNA-REST, as recommended for commercial reagents. Span NP were less toxic for human MSCs than LNCs, but although both NP showed a similar inhibition of REST over time and the induction of neuronal commitment, LNC-siREST induced a higher expression of neuronal markers. Therefore, two different tailored siRNA NP offering great potential for human stem cell differentiation have been developed, encouraging the pursuit of further in vitro and in vivo in studies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mesenchymal stem cells; Nanocarriers; Neuronal differentiation; REST; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26617318     DOI: 10.1016/j.ijpharm.2015.11.020

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

Review 1.  Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair.

Authors:  Andrea Lolli; Letizia Penolazzi; Roberto Narcisi; Gerjo J V M van Osch; Roberta Piva
Journal:  Cell Mol Life Sci       Date:  2017-04-22       Impact factor: 9.261

2.  A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.

Authors:  Emilie M André; Gaëtan J Delcroix; Saikrishna Kandalam; Laurence Sindji; Claudia N Montero-Menei
Journal:  Pharmaceutics       Date:  2019-10-12       Impact factor: 6.321

Review 3.  Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects.

Authors:  Noha Attia; Mohamed Mashal; Gustavo Puras; Jose Luis Pedraz
Journal:  Pharmaceutics       Date:  2021-06-07       Impact factor: 6.321

4.  Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance.

Authors:  Weihong Guo; Lizhi Deng; Jiang Yu; Zhaoyu Chen; Yanghee Woo; Hao Liu; Tuanjie Li; Tian Lin; Hao Chen; Mingli Zhao; Liming Zhang; Guoxin Li; Yanfeng Hu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.